News Business Sports Entertainment Life Obituaries Opinion
Jobs Homes Cars Classifieds Shopping

Search PB Blogs



876 posts categorized "Mayo Clinic"

November 18, 2015

After demolition, what next for Ronald McDonald House project?

Rochester's Ronald McDonald House plans to demolish two apartment buildings on Second Street Southwest to make way for a possible future project.

Demolition permits were filed for the apartment buildings at 806 and 812 Second St. SW, just east of the Ronald McDonald House at 850 Second St. SW. The nonprofit McDonald House acquired the buildings in January in conjunction with Mayo Clinic, which is partnering on the deal.

564c8711dd9b4.imageThe 35-year-old Ronald McDonald House provides housing for children and their families who are in Rochester for medical treatment at Mayo Clinic. It can house up to 42 families at one time. In 2014, it served 795 families, but had to turn 1,071 families away.

The facility's last expansion was 11 years ago.

"Our Board of Trustees is committed to serving more families," according to Marit Williams, the Ronald McDonald House's communications and community relations coordinator. However, she would not say if the demolition will make way for a future expansion.

"We are committed to serving more families, and in order to allow us to continue focusing on the best possible way to do that, we do not have any expansion-specific information to share publicly at this time," Williams wrote in response to inquiries. "The land is intended to help us continue providing a home-away-from-home and caring support for more families in the future. There are no commercial development plans."

Whatever the future holds, the next step in the project is to knock down the two 1960s brick apartment complexes. Williams confirmed both buildings now are empty of tenants.

"We do not have a firm date for the demolition, but we expect this activity to happen in early winter," she wrote in a recent email.

Both buildings were officially acquired on Jan. 30. The 812 Second Street Street property was purchased by the Ronald McDonald House in a pair of separate deals for $825,500 and $137,500. 

A similar series of transactions occurred for the 806 Second Street building. The Ronald McDonald House paid the estate of John T. Oliphant estate $890,000 on Jan. 2, 2014.

Mayo Clinic then paid the Ronald McDonald House $1 million for both properties on Jan. 30 of this year, according to Olmsted County Property Record.Both the Ronald McDonald House and Mayo Clinic are listed as owners of both apartment complexes.

October 26, 2015

What's Mayo Clinic's plan for its new technology park?

Mayo4710technologyparkMayo Clinic is moving dirt and dividing up some open land by its Rochester data center at 4710 West Circle Dr. N.W.

However, details are sparse about the future of the site.

Mayo Clinic has submitted plans to the city for a "4710 Technology Park," a 22.5 acre tusk-shaped chunk of land north of the 4710 data center building.

The permit says:

 Final Plat #R2015-030PLAT to be known as 4710 Technology Park. The Plat proposes to subdivide three lots and one block for commercial development. The property is located at 4710 West Circle Dr NW.

I started asking Mayo Clinic about this project on Sept. 10. Mayo Clinic has not responded yet.
While no building is drawn on the plat, there are a series of driveways/st 10262015mayo4710techparkreets that curve around a space on Plot 2, that would seem to be designed to provide access to some sort of facility.
Mayo Clinic has certainly shown a lot of interest in that northwest area of the Med City for the past several years.
In 2000, it purchased a facility that Western Digital built at 4001 41st St. N.W.That became the Mayo Support Center, which houses Mayo Clinic's Dept. of Defense Medical Research Office spearheaded by Dr. Barry K. Gilbert.
In 2004, it bought a nearby complex at 3050 Superior Drive from Celestica. That eventually became the Superior Drive Support Center, which houses Mayo Medical Labs.
Mayo Clinic then built the 4710 Building, a data center, in 2012. It stands just north of the Mayo Support Center.
And now it is carving out a 4710 Technology Park by the 4710 Building.
In July, Mayo Clinic bought a nearby former mail processing center at 3939 Valleyhigh Drive. No word yet on how that will be used, though there is speculation that it could become a commercial laundry.


October 19, 2015

Does Mayo Clinic + ex-US Postal center = dirty laundry?

Is dirty laundry in the mix as Mayo Clinic figures out how to use the ex-U.S. Postal Service facility it bought in July?

The buzz in the local spin cycle is that Mayo Clinic might convert the 72,662-square-foot facility at 3939 Valleyhigh Drive into a commercial laundry. Right now, Mayo Clinic contracts with the Kahler Hospitality Group's Textile Care Services to clean the mountains of dirty linen it produces every day.

FireShot Capture - 3676 Valleyhigh Dr NW - Google Maps_ - original Kahler Hotel owners and Mayo Clinic started TCS in 1918 as a joint operation. Mayo Clinic pulled out of ownership in 1996 and has contracted with Textile Care ever since.

Officials at Textile Care had no comment on the rumor. Mayo Clinic didn't really answer the question, but it did offer up a cryptic statement.

6a00d83451cc8269e2014e889d360b970d-800wi"No decisions have been made regarding use of the former U.S. Postal building. Mayo Clinic has an agreement with Textile Care Services that extends into 2018 and potentially longer," wrote Mayo's Kelley Luckstein in an email.

So … does that mean maybe? I guess it'll all eventually come out in the wash.

October 01, 2015

A Mayo Clinic linked firm working with DMC planner to develop new Madison biosciences hub

A firm with deep ties to Mayo Clinic is making a move to anchor a downtown Madison, Wis., biosciences hub with help from the development manager of Rochester's Destination Medical Center initiative.

Exact Sciences Corp. licensed technology from Mayo Clinic in 2009 and 2012 for Cologuard, a stool-based DNA test for colorectal cancer. The test is based on research by Mayo Clinic's Dr. David A. Ahlquist and his laboratory.

LogoOriginally based in Boston, city officials at one point hoped Exact would move to Rochester. However, Madison gave the company $1 million to move its headquarters there in 2009.

Since then, the company has flourished, and now it's planning to build a new $200 million, 250,000-square-foot headquarters in downtown Madison with $46.7 million in financial aid from the city.The Madison City Council recently OKed the deal, which requires that Exact will have 400 employees in the building by 2019.

The developer of the project is JDS Development LLC, which is a joint venture between Hammes Co. and Majestic Realty. Hammes is the Wisconsin consultant that is in charge of DMC. It also is working directly with Mayo Clinic on the Discovery Square portion of the DMC project. Hammes also has been hired by the Rochester Convention and Visitors Bureau to do a feasibility study for the proposed hockey arena to house a possible US Hockey League team here.

Hammesco_blue_logoHammes' Exact development will include a 250 room hotel, a food court, health and wellness facility, conference and media centers and lots of room for retail and restaurants.

Exact CEO Kevin Conroy told the Madison City Council that, "We hope that by having a life science company headquarters in downtown Madison, it will spur economic development throughout the region and have a positive impact on downtown."

September 01, 2015

Celyad, Medisun collaborating on new China deal

Two international firms with deep Mayo Clinic and Rochester ties are joining forces for a new $22.4 million collaboration. 

Belgium-based Celyad, formerly called Cardio3, announced Monday it's entering into a new venture and distribution deal with its partner, Medisun International Limited, for its C-Cure cardiac treatment. C-Cure is based on stem-cell technology called cardiopoiesis licensed from Mayo Clinic.

CelyadBoth Celyad and the Hong Kong-based Medisun continue to collaborate with Mayo Clinic and both are in the process of creating facilities in Rochester.

This new 15-year agreement between Celyad and Medisun guarantees Celyad will "conduct all clinical development and undertake any regulatory steps necessary for market approval in China, Hong-Kong, Taiwan and Macau (collectively 'Greater China')," according to a news release about the venture.

Medisun will fund that push with a minimum of 20 million Euros, or $22.4 million. In addition to the funding cash, Celyad will collect royalties and profit sharing. The royalty rates, based on the total revenues from C-Cure, are expected to range from 10 percent to 30 percent. Profit-sharing amounts will be based on total revenues after royalties are taken out. The profit sharing is expected to range from 20 to 25 percent.

"We are pleased to have this new license agreement in place with our local partner Medisun, which give us full control over clinical developments in these territories, fully funded by our local partner. Pending receipt of necessary approvals, we look forward to giving access to this technology to patients in Greater China," stated Celyad CEO Christian Homsy in the release.

6a00d83451cc8269e201b8d0c98293970c-120wiCelyad is paying rent on the entire fifth floor, or 14,963 square feet, in the city of Rochester's Minnesota Biobusiness Center. The city signed a lease with Celyad earlier this year for it to develop a prototype manufacturing facility in the downtown building. Construction has been underway for months, but is not yet completed. The five-year lease calls for Celyad to pay a rent of $18 per square foot, or $22,444.50 per month. The city agreed in the lease to pay for $600,000 in equipment and improvements to the space.

Local officials hope to convince Celyad to build a 100,000-square-foot manufacturing facility with 350 employees in Rochester, according to officials at Rochester Area Economic Development Inc.  Celyad also has plans to build a U.S. headquarters in Boston.

The company recently reported a $17.04 million loss for the first half of 2015. It lost $18.1 million for the whole year in 2014, up from $15.9 million in losses in 2013. Dr. Homsy told Reuters last week the company has enough cash to make it through the end of 2017.

The company did an initial public stock offering in 2014, which yielded about $500,000 worth of shares for Mayo Clinic.

Medisun also is collaborating with Mayo Clinic on a project to bring more patients from China to Rochester for treatment. While Medisun began building a $1 million office in the H3 Plaza building in downtown Rochester earlier this year, it recently put an end to that project.

Mayo Clinic, however, has confirmed it still is working with Medisun. Mayo Clinic spokeswoman Duska Anastasijevic said she didn't believe "the scope and nature of the relationship has been impacted or altered, just the planned location of their offices has changed." 

She added that Mayo staff working with Medisun said the company will be using one of its Rochester homes as "a guest house" and headquarters for the project. Medisun CEO Danny Wong personally owns two houses in Rochester. He bought a house at 2515 Crest Lane SW for $1.4 million as well as one at 615 10th Ave. SW for $1.31 million. It is not known which property will serve as the guest house.

August 19, 2015

Mayo Clinic officially opens Mayo Medical Labs expansion

About a year after breaking ground on the project, Mayo Clinic officially opened a 60,000-square-foot expansion of its Superior Drive Support Center on Tuesday.

The Superior Drive Support Center, which houses Mayo Medical Laboratories, is located at 3050 Superior Drive NW. The three-story addition built on the south side of the complex. Mayo Clinic is moving its the toxicology, endocrinology and proteomic core labs to the new space from downtown. They expect to be fully moved in by April.

Moving those three labs out of the Hilton Building will open up 24,000-square-feet of space. While this expansion will not bring new jobs, it will mean moving 150 to 170 people out of downtown to join the more than 1,000 Mayo Medical Labs employees at the Superior Drive complex.

"That's essential to allow other Mayo labs to decompress," said Dr. Matt Binnicker, the chair of the Department of Laboratory Medicine and Pathology's Facilities and Space Committee, in 2014. "Having those labs here makes a lot of sense."

Mayo Medical Labs, which generates revenue for Mayo Clinic, performs about 20 million tests for more than 4,000 hospitals annually.

Binnicker explained that while the three labs handle tests for both Mayo Clinic's patients and Mayo Medical Labs clinical customers, about 90 to 95 percent of their work is for MML.

Mayo Clinic moved into the 13-year-old complex in 2004. By 2011, about 800 employees worked at the facility. It originally was built by electronics manufacturer Celestica Inc. in 2001. When that company closed its Rochester operation, the building was left empty.

Mayo Clinic leased the property for eight years, until it paid $18.5 million in August 2012 to buy it. Before that, it was owned by 17 national investors through Triple Net Properties of Santa Ana, Calif., until they defaulted on the mortgage in 2012. The investors bought the property for $36.8 million in 2006.

When the mortgage defaulted, HSBC Bank USA took over the property. HSCB then sold it to Mayo Clinic.

While it originally was under construction, New York City-based W. P. Carey & Co. LLC bought the complex from Celestica, which leased it back. W.P. Carey later sold it for about 70 percent more than the $21.6 million it paid.

August 10, 2015

TapImmune using Mayo Clinic tech for possible cancer vaccine


Assistant Manager Editor Mike Klein spotlighted a press announcement from a Seattle-based biotech company called TapImmune Inc. working with Mayo Clinic this morning.

I remember in 2010, when TapImmune first licensed Mayo Clinic technology and began collaborating with Mayo's world-renowned vaccine exTapimmunelogopert, Dr. Gregory Poland.

At that point, they were working with a Small Pox construct to create the vaccine for cancer as well as other infectious threats like, Ebola.

In May of this year, reports came out about Mayo Clinic's Dr. Edith Perez saying how this vaccine changed her view towards preventative medicine. She is working with TapImmune oon applying the vaccine to fight breast cancer.

TapImmune had only $142,000 in and $3.3 million in losses at that point in May.

This appears to be a promising company with deep ties to Mayo Clinic. It seems like a good candidate to based in Rochester rather than someplace like Seattle.

Here's some of what Klein filed on this for today's paper:

Seattle-based TapImmune Inc. has exercised its option agreement with Mayo Clinic to use its technology in a possible vaccine for certain types of cancer, it announced.

TapImmune signed a worldwide exclusive license agreement to commercialize a "proprietary folate receptor alpha vaccine technology for all cancer indications."

This technology, developed in the laboratory of Keith Knutson at Mayo, has successfully completed Phase I clinical trials in ovarian and triple-negative breast cancer. The trial demonstrated the experimental therapy was "safe, well-tolerated, provided a robust immune response," according to the news release. Next, TapImmune plans a Phase II clinical trial in the second half of the year.

TapImmune CEO Dr. Glynn Wilson said the company's future clinical programs will be "aimed at developing this leading vaccine candidate as a stand-alone therapy or in combination with other immunotherapies."

Mayo Clinic has a financial interest in the technology.

August 05, 2015

Insurer expands relationship with Mayo Clinic to bring more patients here

Two Minnesota health-care giants, Mayo Clinic and UnitedHealth Group, are joining forces to bring thousands of new patients to Rochester and other Mayo sites for treatment.

The Eden Prairie-based insurance provider UnitedHealth announced today it will recommend that patients with certain conditions travel to Mayo Clinic for care, through UnitedHealth's Optum Centers of Excellence Program.

800px-Gonda_building,_closer_upCompanies can sign up for coverage under the Centers of Excellence through UnitedHealth or directly through Optum. That means referring patients to designated sites, such as Mayo Clinic's campuses in Rochester, Florida and Arizona, for treatment. Participating in the program may include some coverage of travel and lodging costs.

Mayo Clinic has been listed by Optum as a Center for Excellence for organ transplants for 11 years. Optum says it makes more than 14,000 transplant referrals a year. Neither group said how many Optum organ transplant referrals come to Mayo Clinic each year.

Today's announcement adds the three Mayo Clinic locations to the list of preferred sites for treatment of cancer, heart failure, congenital heart disease, infertility and bariatric surgery.

“This expanded relationship with Mayo Clinic provides patients in participating health plans from around the country with greater access to clinically superior, cost-effective health care,” stated Mike Weissel of Optum Consumer Solutions in today's announcement.

Neither Mayo Clinic nor UnitedHealth released any estimates on how many more patients this might bring to Mayo Clinic or how much money it might bring in for Mayo Clinic. However, it clearly could be a great boon for the medical center and communities such as Rochester.

All of the new conditions added to list are major medical treatments. A look at just bariatric surgery shows the potential for growth. 

Mayo Clinic reports it performs more than 300 bariatric surgeries a year in Rochester. The American Society for Metabolic and Bariatric Surgery estimated a total of 179,000 bariatric surgeries were performed in the U.S. in 2013.

Both Mayo and Optum stressed how this new relationship will benefit patients by providing "access to high-quality, cost-effective care."

“Health plans and employers know the value of sending patients with complex and or rare conditions to high-quality centers such as Mayo Clinic,” said Dr. Charles Rosen, Mayo Clinic's medical director of contracting and payer relations.

Today's announcement marks the latest collaboration between Mayo Clinic and UnitedHealth/ Optum. Earlier this year, Mayo Clinic announced its partnership with Optum360 for revenue management services.

In 2013, they launched "a strategic research alliance"  to create a state-of-the-art facility in Cambridge, Mass under the umbrella of OptumLabs. OptumLabs is a for-profit unit of UnitedHealthcare's Optum division, which earned $1.3 billion in 2011. 

The research facility today has 22 major corporate partners and has more than 100 studies in process.

Boston Scientific buys major stake in local firm, Preventice

Preventice Solutions, a maker of wearable cardiac monitors with deep Rochester roots, is getting a major boost from a medical giant.

Boston Scientific Corp. announced Tuesday it now is "a significant shareholder" in Preventice as well as its "exclusive worldwide sales and marketing representative."

Preventice, which has a large development center in northwest Rochester, makes the wearable BodyGuardian Remote Monitoring System, developed from research licensed from Mayo.

144536The new deal clears the way for Preventice to reach the remote monitoring market estimated to total $19 billion to $21 billion by 2016. Experts anticipate almost five million patients will be using some type of wireless monitoring by then.

"As our health-care environment continues to evolve, health-care practitioners, administrators and payors are looking for solutions that identify relevant clinical insights from large volumes of patient data and integrate those insights to improve clinical decision-making," said Boston Science Executive Vice President Joe Fitzgerald in Tuesday's announcement.

Fitzgerald described Preventice as having "an infrastructure optimized to monitor hundreds of thousands of patients each year."

The privately owned firm has grown quickly since being launched in 2007 with only its founders on staff. Preventice evolved from Boost Information Services. It was founded by Jon Otterstatter, Greg Wobig, Dan Spors and Scott Burrichter.

Preventice started as a developer of medical information smartphone apps, in collaboration with Mayo Clinic and Merck. Then it shifted gears to begin developing wearable cardiac monitors. The U.S. Food and Drug Administration approved its wireless BodyGuardian monitor to be prescribed to track nonlethal arrhythmia, or irregular heartbeats, in 2012.

In 2013, Preventice began shipping out its BodyGuardian systems to feed what CEO Otterstatter described then as the health-care industry's growing "fever" for remote medical monitoring. That year, it expanded to about 100 employees, with about half in Preventice's Rochester offices. Based in Minneapolis, Preventice also has an office in Fargo, N.D.

Preventice Solutions merged with Houston, Texas-based eCardio Diagnostics in 2014, under the holding company of Preventice Inc.

July 23, 2015

Quiet period to end for Celyad (former Cardio3) on July 29

Here's an interesting update from a site called about the former Cardio3, now trading in U.S. as Celyad. This Belgium firm has deep ties to Mayo Clinic and will soon occupy an entire floor of the Minnesota Biobusiness Center in downtown Rochester.

 Celyad SA’s  quiet period is set to expire on Wednesday, July 29th. Celyad SA had issued 1,460,000 shares in its initial public offering on June 19th, Market Beat reports.

CelyadThe total size of the offering was $100,097,600 based on an initial share price of $68.56. During Celyad SA’s quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.


CYAD has been the subject of a number of recent recent research reports. Analysts at Piper Jaffray initiated coverage on shares of Celyad SA in a research note on Tuesday, July 14th. They set an “overweight” rating and a $95.00 price target on the stock. Separately, analysts at Maxim Group reiterated a “buy” rating on shares of Celyad SA in a research note on Sunday, June 21st.

Celyad SA remained flat at $60.44 during during mid-day trading trading on Wednesday. 126 shares of the company’s stock traded hands. Celyad SA has a one year low of $47.52 and a one year high of $67.94. The stock’s 50-day moving average is $54.65 and its 200-day moving average is $54.65.